Disease relevance of C07124

• CONCLUSION: Flomax appears to be effective in relieving the symptoms of radiation urethritis [1].
• After correcting for the testing of multiple hypotheses (n = 5), the presence of benign prostatic hyperplasia (BPH) approached statistical significance for predicting the initial response to the 0.4 mg dose of Flomax (78% vs. 25%, p = 0.03) [1].
• YM-617 caused dose-dependent decreases in renal sympathetic nerve activity along with this hypotension [2].
• Intravenous administration of YM-617 (2, 10 and 50 micrograms/kg) produced a dose-dependent reduction in mean arterial pressure accompanied with bradycardia [2].
• METHODS AND MATERIALS: From January 1998 to April 1998, 26 consecutive patients who developed symptoms of radiation urethritis while undergoing RT for prostate cancer were treated with Flomax, a superselective alpha1A-adrenergic antagonist [1].

High impact information on C07124

• L(-) norepinephrine causes a time-dependent (t1/2 = 22 min) histamine release; the alpha 1-receptor antagonists WB-4101 and YM-617 specifically inhibited this release, in agreement with a mediation by alpha 1-adrenoreceptor subtype [3].
• The present study was undertaken to elucidate the effect of YM-617 on sympathetic nerve activity and baroreceptor afferent nerve activity in anesthetized rats [2].
• The mean pA2 value for R-(-)-YM-12617 at the alpha-1 adrenoceptor of trigone, urethra and prostate was 9.91, 9.62 and 9.92, respectively, and that for S-(+)-YM-12617 was 8.09, 7.92 and 7.77, respectively [4].
• Intraoperative floppy-iris syndrome (IFIS) is a recently identified condition associated with phacoemulsification in patients using the alpha(1)-antagonist tamsulosin (Flomax) [5].
• Contractions elicited by the specific alpha 1-receptor agonist phenylephrine (PE) were inhibited by the selective alpha 1-receptor antagonists prazosin and YM 617 [6].

Chemical compound and disease context of C07124

• PURPOSE: To report choroidal detachment following tamsulosin (Flomax, an alpha(1A)-adrenoceptor antagonist) treatment of benign prostatic hyperplasia (BPH) [7].

Associations of C07124 with other chemical compounds

• The selective alpha 1-receptor agonist, phenylephrine (PE), induced fully reversible, dose-dependent contractions antagonized by increasing concentrations of the alpha 1-receptor blockers prazosin (1-100 nM) and YM 617 (0.1-10 nM) [8].

References